ReviewMinerva surgery2025
Current insights into breast and ovarian cancer risk: a contemporary review.
Review in Minerva surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification and Computational Analysis ofMedical sciences (Basel, Switzerland) · 2026Article
- Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).Oncology letters · 2026Review
- Gene driven analytical learning model for accurate breast cancer diagnosis.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Breast and ovarian cancer account for millions of new cancer diagnoses worldwide annually. An individual's risk of breast and/or ovarian cancer is the result of a complex interplay between non-modifiable and modifiable factors. This review provides a comprehensive map of the current state of our understanding of breast and ovarian cancer risk as conducted through a literature review utilizing PubMed and Cochrane review as primary databases and the selection process prioritized year of publication for up-to-date research and journal impact factor as criteria of research credibility. We review non-modifiable risk factors, such as genetic variations, age, sex assigned at birth, and reproductive history as well as how advances in genetic mapping have led to increased insight in pathogenic germline variants. Additionally, we discuss modifiable factors such as lifestyle and environmental exposures which allow the opportunity for intervention to reduce risk. Contemporary high risk screening tools, including understanding their strengths and weaknesses, are discussed and how they can lend to the determination of eligibility for preventive measures, including risk-reducing operations. The unique challenges of under-represented groups, such as non-Hispanic Black women, transgender/nonbinary/and gender-diverse individuals, and Asian and Pacific Islander populations are reviewed in the context of breast and ovarian cancer risk. Future research on improving risk assessment tools and identifying genomic variants will yield improved personalized healthcare solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.